Insulin glulisine

Drug Profile

Insulin glulisine

Alternative Names: 1964; Apidra; HMR 1964

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 17 Feb 2017 Sanofi re-initiates a phase I bioequivalence trial for Type-1 diabetes mellitus in Germany (NCT02910518)
  • 01 Nov 2016 Sanofi suspends a phase I bioequivalence trial for Type-1 diabetes mellitus in Germany (SC) (NCT02910518) due to unavailability of clinical supplies
  • 25 Jun 2011 Efficacy data from the phase IV 'All to Target' trial in type 2 diabetes presented at the 71st Annual Scientific Sessions of the American Diabetes Assocation (ADA-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top